In the context of cancer therapy, particularly in solid tumors, BsAbs provide a multifaceted approach to immunotherapy by simultaneously targeting PD-(L)1 and other immune regulatory molecules, such as anti-CD47/PD-L1, anti-PD-1/CTLA-4, and anti-4-1BB/PD-L1. Here, PDCD1 is linked to cancer.